Previous close | 18.14 |
Open | 0.00 |
Bid | 17.93 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 173,245 |
Market cap | 3.573B |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.58 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights The considerable ownership by individual investors in Evotec indicates that they collectively have a...
Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript November 11, 2023 Werner Lanthaler: Welcome to our — good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D. That’s how we titled this presentation, which we have uploaded to the Internet and you are welcome to join this call also […]
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an